Fresenius stock gains as FMC sale raises EUR 524 million

Fresenius completed the sale of 13.4 million shares in Fresenius Medical Care on Thursday, November 12, according to an ad-hoc-news.de report carrying the company's announcement. The accelerated bookbuild placed the shares with institutional investors at EUR 39.00 each and generated gross proceeds of approximately EUR 524 million.

Fresenius's financial investment in Fresenius Medical Care falls from approximately 25% to approximately 20% of issued share capital. The transaction continues the Bad Homburg-based healthcare group's strategy of managing the holding as a financial investment rather than consolidating Fresenius Medical Care's operating results.

Proceeds Support FutureFresenius

Fresenius said the net proceeds will be available for its growth platforms and other capital allocation priorities under the FutureFresenius strategy. Chief Financial Officer Sara Hennicken described the transaction as another step in the disciplined management of the Fresenius Medical Care investment and linked the released capital to the company's REJUVENATE phase.

Settlement is expected on Monday, November 16. Fresenius has agreed to a 90-day lock-up on its remaining Fresenius Medical Care shares, subject to customary exceptions. The company expects a book gain in the low to mid double-digit million euro range, which will be recorded in fourth-quarter 2026 results as a special item.

Fresenius stock traded at 54.03 euros on Lang & Schwarz at 11:51 CET on Thursday, November 12, 2.29% above the Xetra close of Wednesday, November 11. The transaction adds financial flexibility, but the eventual effect on Fresenius depends on how quickly the proceeds are redeployed into the group's growth platforms and on operating performance at Kabi and Helios.

The DAX market environment remains the broader reference for Germany-listed healthcare shares.

More news and analyses on Fresenius stock.